Table 1.
Participant demographics and medication history.
| NPNS First (n = 21) | Sham First (n = 18) | Total (n = 39) | |
|---|---|---|---|
| Age, years, mean (SD) | 54.4 (10.7) | 57.7 (14.5) | 55.7 (12.4) |
| Sex, n (%) | |||
| Male | 10 (48) | 7 (44) | 17 (46) |
| Female | 11 (52) | 9 (56) | 20 (54) |
| Race/ethnicity, n (%) | |||
| White, non-Hispanic | 17 (81) | 14 (88) | 31 (81) |
| White, Hispanic | 1 (5) | 2 (13) | 3 (8) |
| Asian | 2 (10) | 0 (0) | 2 (5) |
| Native American | 2 (10) | 0 (0) | 2 (5) |
| Indian | 1 (5) | 0 (0) | 1 (3) |
| IRLS score, mean (SD) | 24.0 (4.0) | 24.1 (3.8) | 24.0 (3.9) |
| Age of onset, years, mean (SD) | 30.7 (18.2) | 39.1 (17.2) | 34.4 (18.0) |
| Duration of symptoms, years, mean (SD) | 23.5 (17.6) | 17.8 (11.6) | 20.9 (15.3) |
| Parent or sibling with RLS, n (%) | 12 (57) | 8 (53) | 20 (56) |
| RLS medication history, n (%) | |||
| Medication-naïve | 7 (33) | 7 (39) | 14 (36) |
| Discontinued medication(s) | 2 (10) | 2 (11) | 4 (10) |
| Medication-resistant | 12 (57) | 9 (50) | 21 (54) |
| Dopamine agonists | 8 (38) | 8 (44) | 16 (41) |
| Benzodiazepines | 3 (14) | 0 (0) | 3 (8) |
| Gabapentin | 1 (5) | 0 (0) | 1 (3) |
| Opioids | 0 (0) | 2 (11) | 2 (5) |
IRLS = International RLS Study Group rating scale, NPNS = noninvasive peripheral nerve stimulation, RLS = restless legs syndrome, SD = standard deviation.